Skip to content

Tarsus Pharmaceuticals, Inc. TARS Lessee, Operating Lease, Liability, Tenant Improvement Allowance

Lessee, Operating Lease, Liability, Tenant Improvement Allowance at other companies

Moelis & Company logo
Moelis & CompanyMC
$1.2M-76.0%
WaFd, Inc. logo
WaFd, Inc.WAFD
$12.31M+27.9%
The Vita Coco Company, Inc. logo
The Vita Coco Company, Inc.COCO
$3.13M+975%
DigitalOcean logo
DigitalOceanDOCN
$62.69M+93.5%
TFS Financial logo
TFS FinancialTFSL
$4.26M-0.6%
AZZ logo
AZZAZZ
$60.65M+127%

Other financials

Income statement

See full
Revenue$162.1M+107%
Gross profit$152.7M+109%
Operating income-$6.1M+76.7%
Net income-$7.0M+72.3%
EPS (diluted)-$0.16+75.0%

Balance sheet

See full
Cash & equivalents$104.2M-41.6%
Total debt$88.7M+22.5%
Total equity$349.0M+1.9%
Total assets$581.1M+16.1%

Cash flow

See full
Operating cash flow-$24.7M-19.4%
CapEx$5.8M+886%
Free cash flow-$30.5M-43.4%

Valuation

See full
Market cap$2.85B+41.1%
Enterprise value$2.83B+47.8%
P/S5.3×-3.3×

Profitability

See full
Gross margin42.7%
Operating margin-9.5%-4.2pp
Net margin-9%-4.0pp
FCF margin-28%-12.6pp

Returns & leverage

See full
Return on equity-14%-5.2pp
Debt / equity0.3×0.0×
Current ratio3.7×-1.8×

Where this comes from

Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept tars:LesseeOperatingLeaseLiabilityTenantImprovementAllowance.

The official record: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Tarsus Pharmaceuticals, Inc.'s lessee, operating lease, liability, tenant improvement allowance.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Tarsus Pharmaceuticals, Inc.'s lessee, operating lease, liability, tenant improvement allowance?
Tarsus Pharmaceuticals, Inc. (TARS) reported lessee, operating lease, liability, tenant improvement allowance of $592K in Q1 2026.
How has Tarsus Pharmaceuticals, Inc.'s lessee, operating lease, liability, tenant improvement allowance changed year-over-year?
Tarsus Pharmaceuticals, Inc.'s lessee, operating lease, liability, tenant improvement allowance increased by 261.0% year-over-year, from $164K to $592K.
What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s lessee, operating lease, liability, tenant improvement allowance?
Over 2 years (2023 to 2025), Tarsus Pharmaceuticals, Inc.'s lessee, operating lease, liability, tenant improvement allowance has grown at a 573.0% compound annual growth rate (CAGR), from $129K to $5.84M.
What does lessee, operating lease, liability, tenant improvement allowance mean?
This represents the financial obligation arising from operating leases, adjusted for incentives provided by landlords such as tenant improvement allowances. It reflects the net liability a company carries for its leased office or facility space after accounting for capital contributions from the lessor. This metric is essential for assessing the net long-term contractual commitments related to real estate and facility infrastructure.